

PHARMACY FACTS

Program Updates from Louisiana Medicaid

June 28, 2022

Preferred Drug List (PDL) Update

The new PDL will be implemented July 1, 2022 and will be posted at

<https://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>.

There were no new therapeutic classes added to the PDL during the spring 2022 Pharmaceutical & Therapeutics (P&T) Committee review.

Brand Over Generic List: PHARMACISTS – adjust your inventory accordingly

On May 6, 2022, LDH held a virtual Pharmaceutical & Therapeutics Committee review via Zoom. The Louisiana Department of Health's legal department authorized Pharmacy staff to host a review in lieu of an actual meeting due to the constraints of COVID-19 and the current public meeting laws. Since this was a virtual review, it was conducted without the P&T members voting. However, feedback from committee members, the public and drug manufacturers was allowed and taken into consideration.

In addition, the Pharmacy Advisory Council (PAC) members reviewed the Brand over Generic list and provided feedback as well. There are times when brand products are preferred over generics because the net price to the state is less expensive after rebate. After considering the financial and clinical impacts, as well as the feedback on the proposed recommendations, the Brand over Generic List will be as follows effective July 1, 2022:

Brand Over Generic — Spring Review 2022 Effective July 1, 2022 (highlighted drugs are new to the list)	Spring/Fall
AMITIZA (ORAL)	Spring
APRISO (ORAL)	Spring
BETHKIS (INHALATION)	Spring
COPAXONE 20 MG/ML (SUBCUTANE.) – 40mg/ml new Brand Over Generic	Spring – New strength
NATROBA (TOPICAL)	Spring
NEXIUM SUSPENSION (ORAL)	Spring
PROTONIX SUSPENSION (ORAL)	Spring
RAPAMUNE SOLUTION and TABLET (ORAL)	Spring

PHARMACY FACTS

Program Updates from Louisiana Medicaid

RENEVELA TABLET (ORAL)	Spring
RETIN-A CREAM (TOPICAL)	Spring
REVATIO SUSPENSION (ORAL)	Spring – New
SUBOXONE FILM (SUBLINGUAL)	Spring
ADDERALL XR	Fall
ADVAIR DISKUS (INHALATION)	Fall
AFINITOR (ORAL)	Fall
ALPHAGAN P 0.15% (OPHTHALMIC)	Fall
BANZEL TABLET AND SUSPENSION	Fall
CARBATROL (ORAL)	Fall
CIPRODEX (OTIC)	Fall
DEPAKOTE SPRINKLE (ORAL)	Fall
DIASTAT RECTAL	Fall
ELIDEL (TOPICAL)	Fall
SABRIL TABLET and POWDER PACK (ORAL)	Fall
SYMBICORT (INHALATION)	Fall
TEGRETOL XR (ORAL)	Fall
TOBRADEX SUSPENSION (OPHTHALMIC)	Fall
TRAVATAN Z (OPHTHALMIC)	Fall
TRILEPTAL SUSPENSION (ORAL)	Fall

Remove Brand Over Generic Products – Spring 2022	Spring/Fall	Notes
CATAPRES-TTS (TRANSDERM)	Fall	Brand and generic preferred
CHANTIX	Fall	Brand and generic preferred
FELBATOL TABLET (ORAL)	Fall	Brand and generic preferred
GEODON (INTRAMUSC)	Fall	Brand and generic preferred
IMITREX (NASAL)	Spring	Brand and generic preferred
LIALDA (ORAL)—considered but not adding	Spring	Brand and generic NP
SAPHRIS	Fall	Brand and generic NP
SUTENT	Fall	Brand and generic preferred
TECFIDERA and TECFIDERA STARTER PACK (ORAL)	Spring	Generic preferred, brand NP
ZAVESCA	Fall	Brand and generic NP

PHARMACY FACTS

Program Updates from Louisiana Medicaid

Synagis (palivizumab) Season

Effective July 1, 2022, the Louisiana Medicaid Fee for Service (FFS) Pharmacy Program and Managed Care Organizations (MCO) will expand palivizumab (Synagis®) coverage. For Louisiana, the typical respiratory syncytial virus (RSV) season begins November 1 and lasts through March 31. Based on expert opinion and Centers for Disease Control (CDC) National Respiratory and Enteric Virus Surveillance System (NREVSS) data, a decision was made to allow palivizumab dosing outside the usual RSV season beginning July 1, 2022. The expanded coverage will include pharmacy claims for palivizumab (Synagis®) submitted at Point of Sale (POS) during the off-season (July 2022 - October 2022) as well as the RSV Season (November 2022 - March 2023). The coverage applies to pharmacy claims submitted to FFS and Louisiana Medicaid MCOs (Aetna, AmeriHealth Caritas, Healthy Blue, Louisiana Healthcare Connections and United Healthcare).

COVID-19 Vaccine Update

Implementing on or before July 5, 2022 with an effective date of June 20, 2022, COVID-19 vaccine coverage as a pharmacy benefit will be updated to include recipients 3 years and older for the Pfizer and Moderna vaccines. The Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) have authorized these vaccines down to 6 months of age, but due to the Public Readiness and Emergency Preparedness (PREP) Act restrictions on pharmacist administration pharmacy claims will only be reimbursed for recipients 3 years and older.

Effective July 1, 2022, the Louisiana Medicaid Fee for Service Pharmacy Program and Managed Care Organizations will update the COVID-19 vaccine administration fee. The current administration fee per injection of the COVID-19 vaccine will be changed from \$37.08 to \$36.78 to align with the Medicare rate and Louisiana Medicaid Professional Services. No dispensing fee shall be reimbursed, only an administration fee. At home, administration of the COVID-19 vaccine for any dose will be changed from \$32.60 to \$32.98 for a total reimbursement of \$69.76 (\$32.98 + \$36.78) or billed charges, whichever is the lesser amount.

Provider Enrollment Portal

Deadline to submit an application to Medicaid Provider Portal – June 30, 2022. Enroll Now!

This message serves as a reminder for all Medicaid providers including pharmacies, immunizing pharmacists and prescribing providers. All providers that file claims with Louisiana Medicaid must enroll in Medicaid's new web-based provider enrollment portal. Federal laws enforced by CMS,

PHARMACY FACTS

Program Updates from Louisiana Medicaid

including the Affordable Care Act and the 21st Century Cures Act, require states to screen and enroll all providers.

The enrollment portal **must be used by all Medicaid providers**. This includes Fee for Service, managed care organization only, Dental Benefits Program Manager (DBPM), Coordinated System of Care (CSoc) providers, pharmacies, immunizing pharmacists and prescribing providers.

The deadline for providers to submit an application to the enrollment portal is June 30, 2022. Any existing Medicaid providers that does not submit an application to initiate the screening process through the new portal will have their claims denied.

Providers can check their enrollment status with the new [Portal Provider Enrollment Lookup Tool](#), available at www.lamedicaid.com. Providers can search for completed enrollments using at least one of several data points – NPI, provider name, provider type, specialty, address, city and state or zip code. Information is updated daily. Results will list which providers have a 100% completed and fully processed enrollment. If a provider has submitted their enrollment but does not see their name listed, their enrollment may still be in process. Providers should allow 15 business days from their submission for their enrollment to be completed. For any enrollment not completed in that time, the provider should reach out to Gainwell Technologies at louisianaprovenroll@gainwelltechnologies.com or by calling 1-833-641-2140 for a status update and any next steps needed to complete the process.

The enrollment portal is accessible through Medicaid's fiscal intermediary website at www.lamedicaid.com. Additional guidance to help providers navigate enrollment can be found at www.ldh.la.gov/medicaidproviderenrollment. The site includes links to FAQs, manuals and training webinars, as well as contact information for providers with questions about enrollment.

If you have further questions, please email LouisianaProvEnroll@gainwelltechnologies.com or call 1-833-641-2140, Monday – Friday between the hours of 8 a.m. and 5 p.m. Central time.